N Engl J Med 2007 Aug 16
Prophylactic cranial irradiation in extensive small-cell lung cancer.
ABSTRACT
BACKGROUND
We conducted a randomized trial of prophylactic cranial irradiation in patients with extensive small-cell lung cancer who had had a response to chemotherapy.
METHODS
Patients between the ages of 18 and 75 years with extensive small-cell lung cancer were randomly assigned to undergo prophylactic cranial irradiation (irradiation group) or receive no further therapy (control group). The primary end point was the time to symptomatic brain metastases. Computed tomography or magnetic resonance imaging of the brain was performed when any predefined key symptom suggestive of brain metastases was present.
RESULTS
The two groups (each with 143 patients) were well balanced regarding baseline characteristics. Patients in the irradiation group had a lower risk of symptomatic brain metastases (hazard ratio, 0.27; 95% confidence interval [CI], 0.16 to 0.44; P<0.001). The cumulative risk of brain metastases within 1 year was 14.6% in the irradiation group (95% CI, 8.3 to 20.9) and 40.4% in the control group (95% CI, 32.1 to 48.6). Irradiation was associated with an increase in median disease-free survival from 12.0 weeks to 14.7 weeks and in median overall survival from 5.4 months to 6.7 months after randomization. The 1-year survival rate was 27.1% (95% CI, 19.4 to 35.5) in the irradiation group and 13.3% (95% CI, 8.1 to 19.9) in the control group. Irradiation had side effects but did not have a clinically significant effect on global health status.
CONCLUSIONS
Prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs disease-free and overall survival. (ClinicalTrials.gov number, NCT00016211 [ClinicalTrials.gov].).
Related Questions
This has become standard practice at our institution for patients with a good performance status, with whole brain radiotherapy given after the comple...
New answer by Radiation Oncologist at University of Colorado School of Medicine (October 2, 2023)
Regarding updates in 2023, as a follow up to FIRE-SCLC (Rusthoven et al., PMID 32496550), our group recently published the CROSS-FIRE study in JNCI (Rusthoven et al., PMID 371...
In the study published by Slotman et al (Lancet 2015), nearly all the patients in the thoracic RT arm started with PCI. For patients with gross diseas...
New comment by Radiation Oncologist at Quillen VA Medical Center ( December 12, 2022)
ASTRO guideline no longer embraces PCI for anyone over 70. Hippocampus sparing has studies supporting it, and not supporting it. Some believe PCI toxicity is frequent. I am no...
New comment by Radiation Oncologist at Northeast Alabama Regional Medical Center ( October 3, 2017)
here's some data (admittedly presented with all the attendant, usual caveats) but compelling nonetheless given the magnitude of the benefits imho
https://www.nature.com/artic...
New answer by Radiation Oncologist at Oregon Health & Science University (June 6, 2018)
No. The role of PCI is currently being reconsidered even for lung small cell lung cancer - where PCI has been established after Auperin meta-analysis in Limited Stage and EORT...
If so, do you allow a period of "washout" between immunotherapy and radiation?
When is the ideal window for delivering PCI for limited-stage SCLC?
New comment by Radiation Oncologist at Ohio State University James Cancer Center ( February 13, 2021)
In MR-screened populations, brain metastasis velocity in LS-SCLC becomes essentially identical in patients who do and do not receive PCI by about 3 months after delivery. ...
New comment by Medical Oncologist at Locum Tenens ( October 18, 2021)
Great idea. The NNT is much more understandable to patients. Thank you.
In elderly patients (>70-75) with a good performance status, does the risk of neurocognitive decline outweigh the benefit of PCI?
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (December 28, 2021)
This is a question that begs for the science and art of oncology. I look at the individual patient, I look at not only calendar age but functional age and comorbidities, and l...
Given that prophylactic cranial irradiation (PCI) has been shown to decrease the incidence of symptomatic brain metastases in patients with extensive ...
New comment by Medical Oncologist at UCLA Health ( October 3, 2021)
Great answer. Thank you
Knowing the OS benefit with the Slotman data in patients who did not have upfront MRIs, and the fact that the Takahashi data would not apply in his ca...
New answer by Radiation Oncologist at Vanderbilt-Ingram Cancer Center (November 15, 2021)
Normally for my ES-SCLC patients, I do discuss the Slotman trial, but generally recommend against PCI based on the Takahashi trial if they can get regular MRIs.However, I beli...